1. INTRODUCTION:

A year's worth of more and more medications are released onto the market. These medications could be brand-new substances or partially altered versions of already-existing ones. In certain circumstances, the pharmacopoeias might not have standards or analytical methods for these medications.^1,2 Therefore, it becomes essential to create more advanced analysis techniques for these medications. As active medicinal substances (API), excipients, therapeutic products, decay products and associated chemicals, residual solvents, etc., analytical methodologies are created and verified. To guarantee the identification, purity, safety, effectiveness and performance of pharmaceutical products, quality control laboratories employ these techniques.^3,4

Figure 1: Analytical method development types

System appropriateness, linearity, precision, accuracy, specificity, robustness, limit of detection, limit of quantification and stability of samples, reagents and equipment are all included in method validation studies.⁵

Table 1: Validation parameters

Accuracy	Degree of concordance between the discovered value and the true value	Recovery 98-102% with 50, 100, 150%
Precision	Degree of agreement between a set of measurements taken under specific conditions from several samplings of the same sample.	RSD< 2%
Specificity	The capacity to evaluate the sample for its possession of several potential components.	No interference
Selectivity	The method's capacity to isolate the analyte from potential contaminants and other elements in the sample	No interference
Detection Limit	Lowest quantity of an analyte which may be detected by the separation	S/N > 2 or 3
Quantitation Limit	Lowest concentration of analyte in a sample that can be accurately and precisely measured quantitatively	S/N > 10
Linearity	Measure of how closely a calibration plot of response against concentration resembles a straight line.	r 2 < 0.999
Range	Interval between the sample's highest and lowest analyte concentrations⁶	80-120%

2. Drug Profile:

1, 2, 3, 6-tetrahydro-1,3-dimethyl-2, 6-dioxo-7H-purine-7-acetic acid with trans-4- [(2-amino-3, 5 dibromophenyl) methyl] is [aminio] Cyclohexanol is Acebrophylline. Acebrophylline reduces inflammation and controls phlegm in the airways.^7,8 It contains theophylline-7-acetic acid and ambroxol. The former promotes the creation of a lung surfactant, while the latter increases ambroxol content in the bloodstream via boosting detergent biosynthesis.⁹

Figure 2: Dissociation of Acebrophylline

3. Reported Analytical Method Development for Acebrophylline:

These days, sophisticated analytical techniques like UV, HPLC and HPTLC—which are often employed for routine or laboratory purposes are of interest for quantification or estimate. During the whole drug development process, from the first phase of research to the release of drug products, chromatographic methods are primarily employed for the qualitative and quantitative evaluation of drug ingredients, drug products and raw materials. For the estimation of raw materials, active pharmaceutical ingredients and pharmaceutical formulations, the advanced analytical techniques are straightforward, reliable and efficient.

3.1 UV Method Development:

The invention of UV spectrophotometric methods offers a quick, easy and economical way to quantitatively estimate pharmaceutical substances in bulk and dose forms. It is widely utilized in dissolution testing, assay assessment and regular quality control. For routine analytical applications the method provides adequate accuracy, precision and repeatability.^10,11

The basic idea of UV-visible spectroscopy is the electrical changes of electrons to higher energy levels that occur when a substance absorbs UV or visible radiation. Beer-Lambert's law,

A = ε l c,

where A is absorbance, ε is molar absorptivity, l is path length, c is concentration, governs the absorbance.

Table 2: UV method development of Acebrophylline

Development and validation of UV spectroscopic method for estimation of Acebrophylline in tablet dosage form¹²	Diluent: Ethanol
	Lambda max: 251 nm
	Melting point: 213-214˚c
Determination of Acebrophylline in bulk and pharmaceutical formulation by uv spectrophotometer¹³	Instrument: Jasco uv- v-550
	Diluent: ethanol
	Lambda max: 274 nm
Simultaneous estimation of Acebrophylline, Montelukast and Levocetrizine dihydrochloride in marketed formulation by UV-spectroscopy¹⁴	Diluent: Methanol
	Lambda max: Acebro = 250.14nm Monteleukast=284.79nm Levocetrizine = 231.27 nm
Q-absorbance ratio method for simultaneous estimation of Acetylcysteine and Acebrophylline¹⁵	Diluent: Distilled water
	Lambda max: Acebro = 274 nm Acetylecys =195 nm
	Isoabsorptive point: 210 nm

3.2 HPTLC Method Development:

For the assessment of medications in bulk and dose forms, HPTLC is a quick and economical analytical method. Multiple samples can be analyzed simultaneously with little solvent usage. The technique is frequently used in standard stability testing and quality control.

Differential interaction between a stationary phase (silica gel plate) and a mobile phase is the basis for HPTLC's component separation, which produces various migration distances. Analytes migrate at varying speeds based on their affinity for each phase when the mobile phase moves up the plate via capillary action. As a result, at particular locations on the plate well-resolved bands appear.¹⁶ The separation is expressed as the retardation factor (Rf)

RF = distance travelled by solute/distance travelled by solvent front

Table 3: HPTLC method development of Acebrophylline

Analytical method development and validation for simultaneous estimation of Acebrophylline and Montelukast sodium in their pharmaceutical dosage form^[17]	Solid phase: Merck HPTLC aluminum plates of silica gel g60 f254, (10 × 10 cm)
	Mobile phase: Chloroform: Ethyl acetate: Methanol: Triethylamine
	Ratio: : 6: 4.5 : 2.5 : 0.8 v/v/v/v
	Detection : 272 nm
	Rf : Acebro = 0.23 ± 0.01 Mont = 0.83 ± 0.01

3.3 HPLC METHOD DEVELOPMENT:

One of the most popular analytical methods is High Performance Liquid Chromatography or HPLC. It is used to analyze about 85% of common medicines. The separation is accomplished by the interaction of the stationary phase and the mobile phase, which are primarily composed of stationary phase and mobile phase with opposite polarity and equipped with high pressure pumps. To achieve the intended separation, the stationary phase and mobile phase must be chosen carefully.¹⁸

The variables that are crucial to method development include the mobile phase's pH, various buffer types, column temperature, sample diluents, detection wavelength and many more.

Table 4: HPLC Method development

Rp-hplc method development and validation for estimation of Acebrophylline¹⁹	Instrument: LC 10 at Shimadzu – spda10a
	Column: sge ss wakosil - ii 5C₁₈ar
	Mobile phase: 25mm Ammonium acetate: Acetonitrile (ph 7.3)
	Ratio: 30:70 v/v
	Detection: 257nm
	Retention time: Acefylline = 3.05 min Ambroxol = 8.59 min
	Flow rate: ml/min
Analytical method development and validation for the estimation of Acebrophylline, Fexofenadine hcl, Montelukast sodium in bulk and marketed formulation by RP-HPLC²⁰	Instrument: Shimadzu UV win software
	Column: Thermoscientfic hypersil bds
	Mobile phase: Phosphate buffer and Acetonitrile
	Ratio: 50:50 v/v
	Detection: 233nm
	Retention time: Fexofenadine hcl = 2.39 min Montelukast = 3.11 min Acebrophylline = 5.26 min
	Flow rate: 0.7ml/min
RP HPLC method development and validation: Simultaneous estimation of Fexofenadine hydrochloride, Montelukast sodium and Acebrophylline in tablet dosage form.²¹	Instrument: Waters Sperisorb
	Column: ODS 1 column
	Mobile phase: 0.1% Triethylamine (adjust p^H 3.2 with orthophosphoric acid) and Acetonitrile
	Ratio: 10:40% v / v
	Detection: 235nm
	Retention time: Fexofenadine = 6.3mins Montelukast na = 5.5mins Ambroxol = 7.2 mins Theophylline = 2.6 mins
	Flow rate: ml/min
Analytical method development and validation of simultaneous estimation of pure and tablet dosage form by rp-hplc²²	Column: Shim-pack solar C₁₈ column
	Mobile phase: Acetonitrile, Methanol and 10mm Na₂HPO₄ buffer
	Ratio: (50:30:20 % v/v/v, ph 5.5).
	Detection: 210 nm
	Retention time:Montelukast = 7.643min, Fexofenadine = 2.117min, Acebrophylline = 3.863min, Rosagiline mesylate = 3.050 min
	Flow rate: 0.8ml/min
Validated UHPLC method for the concurrent determination of Acebrophylline, Montelukast sodium and Fexofenadine Hcl in oral solid dosage forms²³	Column: Phenomenex C₁₈ column (4.6mm x 50mm, 3µm)
	Mobile phase: Buffer (p^H 8.0 Ammonium acetate solution) and Acetonitrile
	Ratio: 1:1v / v
	Detection: 220nm
	Retention time: Theophylline 7acetate = 0.433 min Ambroxol, = 1.203 min Montelukast sodium = 3.125min Fexofenadine = 0.702 min
	Flow rate: 0.5ml/min
Simultaneous estimation of Acebrophylline, Montelukast and Levocetirizine dihydrochloride in marketed formulation by high-performance liquid chromatography method²⁴	Column: Macherey-nagel C₁₈
	Mobile phase: Ammonium acetate buffer of p^H 3.5 (p^H adjusted with glacial acetic acid) and Methanol
	Ratio: 15:85 v/v
	Detection: 230nm
	Retention time: Acebro = 5.287min Monte = 26.856 min Levocet = 6.440min
	Flow rate: 0.6ml/min
Simultaneous estimation method development and validation of Acebrophylline and Doxofylline in tablet dosage form by RP-HPLC method²⁵	Column: Cosmosil c18
	Mobile phase: Methanol: 10mm KH₂PO₄buffer
	Ratio: 70:30 v / v
	Detection: 243nm
	Retention time: Acebrophylline = 4.076min Doxofylline = 5.193min
	Flow rate: 0.8ml/min
Rp-hplc analysis of Acebrophylline in API and capsule dosage form²⁶	Column: C₁₈ (250x4.6mm, 5μm)
	Mobile phase: Acetonitrile and Double distilled water
	Ratio: 70:30v/v
	Detection: 274 nm lambda max
	Retention time: Acebrophylline =1.75 min
	Flow rate: 1 ml/min

Table 5: Stability indicating method development

Stability indicating RP-HPLC method development and validation for simultaneous quantification of Fexofenadine & Acebrophylline drug in bulk and tablet dosage form³¹	Instrument: Waters 2695 with PDA
	Column: Hypersil BDS C₁₈
	Mobile phase: Phosphate buffer and Acetonitrile, ph with Orthophosphoric acid was adjusted to 7.0
	Ratio: 40:60% v / v
	Detection: 230nm
	Retention time: Fexo =3.06 min ; Acebro =6.76 min
	Flow rate: ml/min
	Run time: 10min
Development and validation of stability indicating HPTLC method for estimation of Acebrophylline in their dosage form³²	Solid phase: 6 x 10 Silica gel 60f254 TLC plate
	Mobile phase: Toluene: Methanol: Acetone
	Ratio: 8: 2: 2v/v
	Detection: 247nm
	Rf: 0.49±0.03
A stability indicating RP-HPLC method for simultaneous estimation of Acebrophylline, Montelukast, and Fexofenadine in bulk and pharmaceutical dosage forms.³³	Instrument: Waters alliance-e2695
	Column: Hyper clone 5µ BDS C₁₈ 130a
	Mobile phase: Methanol: Ammonium formate adjusted to p^H-6 and Ortho phosphoric acid
	Ratio: 70:30 v/v
	Detection: 268nm
	Flow rate: ml/min
Development and validation of stability indicating RP-HPLC method for simultaneous estimation of Doxofylline and Acebrophylline in their combine dosage form³⁴	Instrument: IUHPLC_3000plus
	Column: Agilent (250 cm × 4.6 cm) 0.5µm column with20 μl micro-syringe
	Mobile phase: Phosphate buffer (p^H3.0): Acetonitrile
	Ratio: (40:60) v / v
	Detection: 274nm
Development and validation of stability indicating HPTLC method for simultaneous estimation of Acebrophylline and Doxofylline in combined solid dosage form³⁵	Solid phase: Silica gel 60f254 TLC plate
	Mobile phase: Toluene: Methanol: Glacial acetic acid
	Ratio: 6:2:2, v/v/v
	Detection: 250nm
	Rf: Acebro =0.29± 0.05 Doxo =0.64 ± 0.02
Stability indicating HPLC method development for estimation of Montelukast sodium and Acebrophylline in combined dosage form³⁶	Column: RP-18e 5 μm, 250 mm l × 4.6 mm
	Mobile phase: Acetonitrile: Methanol
	Ratio: 60:40 %v/v, (p^H 3.2 adjusted with O-Phosphoric acid)
	Detection: 260 nm
	Retention time: Montelukast sodium=15.49min, Acebrophylline = 3.45 min
	Flow rate: 0.8ml/min

4. DISCUSSION:

Acebrophylline, a xanthine derivative with anti-inflammatory and mucoregulatory effects, is frequently used to treat respiratory conditions either by itself or in conjunction with leukotriene receptor antagonists and antihistamines. Since acebrophylline is found in an increasing number of fixed-dose combinations, it is necessary to develop analytical techniques that are accurate, sensitive, and repeatable for estimating it in pharmaceutical dosage forms and bulk drugs. This review critically examines the stability-indicating, UV, HPTLC, and HPLC analytical techniques that have been reported for acebrophylline.

UV spectrophotometric techniques have been widely documented because of their ease of use, affordability, and applicability for regular quality control examinations. With λmax values ranging from 250 to 274nm, several investigations used a variety of solvents, including distilled water, methanol, and ethanol. Even though UV techniques provide respectable linearity, accuracy, and precision, their main drawback is their low specificity, especially when dealing with multi-component formulations and degradation products. This limits their use in complex formulations and stability tests.

Low solvent consumption, simultaneous analysis of several samples, and shorter analysis times are some benefits of HPTLC techniques. Good resolution and respectable Rf values were demonstrated by reported HPTLC techniques for Acebrophylline, either by itself or in conjunction with Montelukast or Doxofylline. Nevertheless, HPTLC techniques are less appropriate for trace-level impurity or degradation product characterization and typically show poorer sensitivity when compared to HPLC.

Because of its excellent sensitivity, specificity, and repeatability, Reversed phase HPLC is still the most used method for analyzing acebrophylline. Numerous mobile phases have been documented, including phosphate buffers, ammonium acetate buffers, and organic modifiers such methanol and acetonitrile. The majority of techniques used C18 columns that detected UV light between 210 and 274nm. Acebrophylline has been successfully estimated simultaneously with Montelukast, Fexofenadine, Levocetirizine and Doxofylline with acceptable system suitability characteristics. greater run times and higher solvent consumption resulted from some described methods' greater retention times for co-formulated medications.

Understanding degradation behavior and guaranteeing drug safety depend heavily on stability-indicating techniques. In forced degradation conditions, a number of stability-indicating RP-HPLC and HPTLC techniques have been published that can separate acebrophylline from its breakdown products. Notwithstanding these developments, the majority of research focuses mostly on method validation in accordance with ICH criteria, with little attention paid to the analysis of degradation products.

Overall, the reviewed literature shows that even though there are many analytical approaches for estimating acebrophylline, there is still a lot of room for development in terms of sensitivity, shorter run times, environmental sustainability and sophisticated detection methods.

5. CONCLUSION:

The reported analytical techniques created for the determination of Acebrophylline in pharmaceutical dosage forms and bulk are thoroughly compiled in this study. For regular analysis, UV spectrophotometric techniques are straightforward and cost-effective, although they are not very specific. While RP-HPLC techniques continue to be the gold standard because of their accuracy, robustness and suitability for stability studies and complex formulations, HPTLC techniques offer quick, economical analysis with modest sensitivity.

Understanding the degrading behavior of acebrophylline has been greatly aided by stability-indicating techniques; nonetheless, the majority of described techniques are restricted to standard chromatographic settings with UV detection. The literature makes it abundantly evident that traditional analytical methods are still used, underscoring the necessity for more contemporary, considerate and ecologically friendly methods. Even though there are a number of approved techniques for analyzing Acebrophylline, there is still need for creating novel analytical approaches that meet modern regulatory requirements, green analytical chemistry concepts and sophisticated instrumental capabilities. By using these available methods in biological and clinical analysis of drugs can achieve significantly higher accuracy, sensitivity and efficiency leading to more reliable therapeutic outcomes and improved patient safety.

6. REFERENCES:

1. Gupta A, Rawat S, Gandhi M, Yadav JS. Method development and acid degradation study of doxofylline by RP-HPLC and LC-MS/MS. Asian J. Pharm. Ana. 2011 Jan; 1(1):10-3.

2. Sridharan D, Umarani AT, Kumar LP, Chintalapati AD, Ramanaiah MV, Phanikishore Y. Development and validation of UV spectrophotometric method of darifenacin hydrobromide in bulk and tablet dosage form. Asian Journal of Pharmaceutical Analysis. 2011 Jul; 1(3): 43-5.

3. Satyanarayana L, Naidu SV, Rao MN, Latha RS. The estimation of Nilotinib in capsule dosage form by RP-HPLC. Asian Journal of Pharmaceutical Analysis. 2011 Oct; 1(4): 100-2.

4. Rathod SD, Patil PM, Jadhav SB, Chaudhari PD. UV spectrophotometric simultaneous determination of metformine hydrochloride and pioglitazone hydrochloride in combined dosage form. Asian Journal of Pharmaceutical Analysis. 2012; 2(1): 5-9.

5. Gupta SK, Kumar B, Sharma PK. Development and validation of a RP-HPLC method for estimation of Thalidomide in solid dosage form. Asian Journal of Pharmaceutical Analysis. 2013 Jan; 3(1): 17-9.

6. Kasad PA, Muralikrishna KS. Design and validation of dissolution profile of rivaroxaban by using RP-HPLC method in dosage form. Asian J. Pharm. Ana. 2013 Jul; 3(3):75-8.

7. Pozzi E. Acebrophylline: an airway mucoregulator and anti-inflammatory agent. Monaldi Archives for Chest Disease. 2007; 67(2).

8. Agliati G. Acebrophylline in the treatment of chronic obstructive pulmonary disease. Current therapeutic research. 1995 Feb 1; 56(2): 169-75.

9. Nam KD, Seo JH, Yim SV, Lee KT. Bioequivalence Assessment of Acephyll® Capsule to Surfolase® Capsule (Acebrophylline HCl 100 mg) by Liquid Chromatography Tandem Mass Spectrometry. Journal of Pharmaceutical Investigation. 2011; 41(5): 309-15.

10. Chavan P, Bandgar S, Gejage S, Patil S, Patil S. Development and validation of uv spectrophotometric method for estimation of itraconazole in bulk drug and solid dosage form. Asian Journal of Pharmaceutical Research. 2021 Feb 1; 11(1): 13-6.

11. Jogdand S, Mane K, Jadhav R, Dyade GK. AQBD approach in chemo metric assisted method development for the estimation of ciprofloxacin and metronidazole by UV-VIS spectrophotometry. Asian Journal of Pharmaceutical Research. 2022 Jul; 12(3): 183.

12. Patel A, Patil R, Patil S, Sonar KV. Development and Validation of UV Spectroscopic Method for Estimation of Acebrophylline In Tablet Dosage Form.

13. Aligave AR, Dhamne HS, Gaikwad SS, Kondawar MS. Determination of Acebrophylline in bulk and pharmaceutical formulation by UV spectrophotometer. Journal of Current Pharma Research. 2011 Apr 1; 1(3): 267.

14. Mittal M, Upadhyay Y, Anghore DD, Rawal RR. Simultaneous estimation of acebrophylline, montelukast and levocetrizine dihydrochloride in marketed formulation by UV-spectroscopy. World J Pharm Pharm Sci. 2016 Jun 11; 5: 1274-84.

15. Patel TP, Prajapati L, Joshi A, Kharodiya M. Q-absorbance ratio method for simultaneous estimation of acetylcysteine and acebrophylline. World Journal of Pharmaceutical Research. 2015 Mar 1;4(5):1808-16.

16. RK S, Suganya S, Manju AS, Poomalai S. Study on the Related Substance of Lamivudine by A Validated HPTLC Method in Oral Dosage Forms. Asian Journal of Pharmaceutical Research. 2024 Jul; 14(3): 213-20.

17. Vekaria HJ, Jat RK. Analytical Method Development and Validation for Simultaneous Estimation of Acebrophylline and Montelukast Sodium in their Pharmaceutical Dosage Form. Journal of Basic and Applied Scientific Research. 2011; 1(11): 1884-90.

18. Hamza MZ, Kumaraswamy G, Lalitha G, Suthakaran R. Development and validation of RP-HPLC for simultaneous estimation of cefpodoxime proxetil and dicloxacillin sodium tablets. Asian J. Res. Pharm. Sci. 2014 Oct; 4(4): 155-9.

19. Bhavik S, Agarwal SK. RP-HPLC Method Development and Validation for Estimation of Acebrophylline. Asian Journal of Pharmaceutical Research and Development. 2018; 6(6): 56-9.

20. Meharaj S. Analytical Method Development and Validation for The Estimation of Acebrophylline, Fexofenadine Hcl, Montelukast Sodium in Bulk and Marketed Formulation By RP-HPLC. TMP Universal Journal of Advances in Pharmaceutical sciences. 2025 Jun 16; 1(2).

21. Barabde G, Kokate AB, Pataskar P. Rp-HPLC Method Development and Validation: Simultaneous Estimation of Fexofenadine Hydrochloride, Montelukast Sodium and Acebrophylline in Tablet Dosage Form.

22. Thapa S, Pandey BP, Biradar MS. Analytical Method Development and Validation of Simultaneous Estimation of Pure and Tablet Dosage Form by RP-HPLC. Journal of Nepal Chemical Society. 2024 Aug 6; 44(2): 13-22.

23. SM S, Rajendran M. Validated Uhplc Method for the Concurrent Determination of Acebrophylline, Montelukast Sodium, and Fexofenadine Hcl in Oral Solid Dosage Forms.

24. Mittal M, Upadhyay Y, Anghore D, Kumar A, Rawal RK. Simultaneous estimation of acebrophylline, montelukast, and levocetirizine dihydrochloride in marketed formulation by high-performance liquid chromatography method. Pharmaspire. 2018; 10(1): 23-28.

25. Shinde M, Bhawar HS, Shinde GS. Simultaneous estimation method development and validation of Acebrophylline and Doxofylline in tablet dosage form by RP-HPLC method. World Journal of Pharmaceutical Research. 2019; 8(11): 644–57. doi:10.20959/wjpr201911-15741

26. Takkarusu S, Thota S, Raj Kumar V, Neerati V. RP-HPLC analysis of acebrophylline in API and capsule dosage form. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2014; 5(1): 480–486.

27. Lobhe Gayatri A, Amol S, Indrajeet S. Development and validation of a stability-indicating RP-HPLC method for the determination of sitagliptin phosphate and simvastatin in the presence of their degradation products in bulk and binary mixture. Asian J. Res. Pharm. Sci. 2016; 6(3): 191-7.

28. Bhusari VK, Dhaneshwar SR. Development and validation of a stability-indicating hptlc method for the estimation of eszopiclone in pharmaceutical dosage forms. Asian Journal of Research in Pharmaceutical Science. 2021 Sep 1; 11(3).

29. Doshi AN, Kotadiya V, Amita P. A Novel Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Silodosin and Tadalafil in its Synthetic Mixture. Asian Journal of Research in Pharmaceutical Sciences. 2026 Jan 5; 16(1): 20-4.

30. Kathirvel S, Raju R, Seethadevi B, Suneetha A, Pavani J. Stability Indicating RP-HPLC Method for the Determination of Process Related Impurities in Posaconazole API. Asian Journal of Pharmacy and Technology. 2014 Dec 29;4(4):167-78.

31. Yadav R, Khan S, Sharma R, Nagar P, Shriwas S, Patel R. Stability-indicating RP-HPLC method development and validation for simultaneous quantification of fexofenadine and acebrophylline drug in bulk and tablet dosage form. Int J Pharm Sci Med. 2023; 8(1): 8–35. doi:10.47760/ijpsm. 2023.v08i01.002.

32. Nakarani PP, Patel DM. Development and validation of stability indicating HPTLC method for estimation of acebrophylline in their dosage form. Int J Pharm Res Technol. 2013; 3(1): 1–4. doi:10.31838/ijprt/03.01.01

33. Adikay S, Bhavanasi M, Kaveripakam SS. A stability indicating RP-HPLC method for simultaneous estimation of acebrophylline, montelukast, and fexofenadine in bulk and pharmaceutical dosage forms. Int J Pharm Investig. 2023; 13(2): 306–312. doi:10.5530/ijpi.13.2.040

34. Gupta Monika H, Patani P. Development and Validation of Stability Indicating Rp-Hplc Method for Simultaneouse Estimation of Doxofylline and Acebrophylline in Their Combine Dosage Form.

35. Magar S, Biyani K. Development and Validation of Stability Indicating Hptlc Method for Simultaneous Estimation of Acebrophylline and Doxofylline in Combined Solid Dosage Form.

36. Thesia UD, Patel PB. Stability Indicating HPLC Method Development for Estimation of Montelukast Sodium and Acebrophylline in Combined Dosage Form. Inventi Rapid: Pharm Analysis & Quality Assurance. 2013 May 17.

Received on 31.03.2026 Revised on 04.05.2026

Accepted on 05.06.2026 Published on 10.07.2026

Available online from July 25, 2026

Asian Journal of Pharmaceutical Analysis. 2026; 16(3):197-203.

DOI: 10.52711/2231-5675.2026.00030

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Determination of Acebrophylline in bulk and pharmaceutical formulation by uv spectrophotometer13

Analytical method development and validation of simultaneous estimation of pure and tablet dosage form by rp-hplc22

Column: Shim-pack solar C18 column

Column: Phenomenex C18 column (4.6mm x 50mm, 3µm)

Column: Cosmosil c18

Mobile phase: Methanol: 10mm KH2PO4 buffer

A stability indicating RP-HPLC method for simultaneous estimation of Acebrophylline, Montelukast, and Fexofenadine in bulk and pharmaceutical dosage forms.33

Instrument: Waters alliance-e2695

Column: Hyper clone 5µ BDS C18 130a

Mobile phase: Methanol: Ammonium formate adjusted to pH-6 and Ortho phosphoric acid

Determination of Acebrophylline in bulk and pharmaceutical formulation by uv spectrophotometer¹³

Analytical method development and validation of simultaneous estimation of pure and tablet dosage form by rp-hplc²²

Column: Shim-pack solar C₁₈ column

Column: Phenomenex C₁₈ column (4.6mm x 50mm, 3µm)

Mobile phase: Methanol: 10mm KH₂PO₄buffer

A stability indicating RP-HPLC method for simultaneous estimation of Acebrophylline, Montelukast, and Fexofenadine in bulk and pharmaceutical dosage forms.³³

Column: Hyper clone 5µ BDS C₁₈ 130a

Mobile phase: Methanol: Ammonium formate adjusted to p^H-6 and Ortho phosphoric acid